ESC 365 - Efficacy and safety of monoclonal antibodies targeting interleukin-5 and interleukin-4/13 pathways in eosinophilic myocarditis: a single-center experience.

ESC2025 Premium Access

Efficacy and safety of monoclonal antibodies targeting interleukin-5 and interleukin-4/13 pathways in eosinophilic myocarditis: a single-center experience.

Session: Translating improved disease understanding to novel therapies in myocardial disease

Topic: Pharmacotherapy

Speaker: Doctor C. Menghi (Padova, IT)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Caterina Menghi

University of Padua, Padova (Italy)

1 presentation

0 follower

6 more presentations in this session

Macrophage-derived SPP1 exacerbate myocardial injury by interacting with fibroblasts in viral myocarditis

Speaker: Professor B. Han (Jinan, CN)

Clonal haematopoiesis of indeterminate potential and incident cardiomyopathy

Speaker: Doctor Y. Yu (Shanghai, CN)

Cardiac radiation suppresses hypertrophic cardiomyopathy phenotyping in TnT R92Q HCM mice via modulating Ca2+ homeostasis

Speaker: Doctor Y. Huang (Changsha, CN)

Amyloid staining for detection of eosinophil granules in cardiac tissue

Speaker: Doctor T. Kumaki (Niigata, JP)

Ketone body supplementation attenuates myocardial fibrosis in an experimental model of sepsis

Speaker: Mrs N. Maria Vieira (Botucatu, BR)

Access the full session

Translating improved disease understanding to novel therapies in myocardial disease

Speakers: Doctor C. Menghi, Professor B. Han, Doctor Y. Yu, Doctor Y. Huang, Doctor T. Kumaki...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources